Abstract
Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
Originalsprog | Engelsk |
---|---|
Tidsskrift | American Journal of Nephrology |
Vol/bind | 37 |
Udgave nummer | 3 |
Sider (fra-til) | 212-22 |
Antal sider | 11 |
ISSN | 0250-8095 |
DOI | |
Status | Udgivet - 2013 |